MAP3K12: A Protein Involved in Various Cellular Processes (G7786)

Target Name: MAP3K12

NCBI ID: G7786

MAP3K12

MAP3K12: A Protein Involved in Various Cellular Processes

MAP3K12, also known as dual leucine zipper bearing kinase (DLLKK), is a protein that is expressed in various tissues of the body, including muscle, liver, and brain. It is a non-catalytic RNA-protein kinase that is characterized by its unique structure, which consists of a dual leucine zipper-like region and a catalytic kinase domain.

The dual leucine zipper-like region of MAP3K12 is a unique feature that gives it its name. This region consists of two distinct domains: a N-terminal domain that contains a leucine zipper-like structure, and a C-terminal domain that contains a catalytic kinase domain. The N-terminal domain is responsible for the formation of the zipper-like structure, while the C-terminal domain is responsible for the catalytic activity of the kinase.

The catalytic kinase domain of MAP3K12 is a key regulator of various cellular processes, including cell growth, differentiation, and inflammation. It is known to play a role in the regulation of protein stability, protein-protein interactions, and DNA replication. In addition, the catalytic kinase domain of MAP3K12 is also involved in the regulation of cell signaling pathways, including the TGF-β pathway.

MAP3K12 has also been shown to be involved in the regulation of cellular transport processes. For example, studies have shown that MAP3K12 is involved in the regulation of the trafficking of various proteins, including the protein known as GLUT1. GLUT1 is a glucose transporter that is expressed in various tissues of the body, including muscle, liver, and brain. It is known to play a key role in the regulation of glucose uptake and storage in these tissues.

In addition to its role in cellular signaling and transport processes, MAP3K12 has also been shown to be involved in the regulation of cellular processes related to inflammation. Studies have shown that MAP3K12 is involved in the regulation of the production of pro-inflammatory cytokines, such as TNF-伪 and IL-1尾. In addition, MAP3K12 has also been shown to play a role in the regulation of the apoptosis, which is a process that is involved in the elimination of damaged or dysfunctional cells.

Despite its involvement in a wide range of cellular processes, MAP3K12 is not yet a well-established drug target or biomarker. There are currently no known drugs that are specifically designed to target MAP3K12. However, the catalytic kinase domain of MAP3K12 is an attractive target for drug development, as it is known to play a role in the regulation of various cellular processes. In addition, the dual leucine zipper-like structure of the N-terminal domain of MAP3K12 is also a potential target for small molecules that can modulate the activity of this protein.

In conclusion, MAP3K12 is a unique and highly conserved protein that is involved in a wide range of cellular processes. The catalytic kinase domain of MAP3K12 is a potential target for drug development, while the dual leucine zipper-like structure of the N-terminal domain is also a potential target for small molecules that can modulate the activity of this protein. Further research is needed to fully understand the role of MAP3K12 in cellular processes and to develop drugs that can specifically target this protein.

Protein Name: Mitogen-activated Protein Kinase Kinase Kinase 12

Functions: Part of a non-canonical MAPK signaling pathway (PubMed:28111074). Activated by APOE, enhances the AP-1-mediated transcription of APP, via a MAP kinase signal transduction pathway composed of MAP2K7 and MAPK1/ERK2 and MAPK3/ERK1 (PubMed:28111074). May be an activator of the JNK/SAPK pathway

The "MAP3K12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAP3K12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets